GLP-1 Receptor Agonists may sabotage autologous fat graft survival by altering adipocyte biology, scoping review suggests

The widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has led to an increase in patients experiencing facial volume depletion and soft tissue deflation. Autologous fat grafting is the gold-standard solution for these aesthetic concerns, involving the transfer of a patient's own fat cells. However, the fundamental biology of GLP-1 receptor agonism, which promotes weight loss, may inherently conflict with the mechanisms crucial for fat graft survival. This review addresses the critical gap in understanding how these powerful metabolic drugs might impact the viability and integration of transplanted adipose tissue.

This scoping review, adhering to the PRISMA extension for Scoping Reviews (PRISMA-ScR) guidelines, synthesized existing preclinical and clinical evidence. Researchers examined the effects of semaglutide, liraglutide, tirzepatide, and the emerging triple agonist retatrutide on key aspects of adipocyte biology. The analysis focused on adipocyte metabolism, the function of adipose-derived stem cells (ASCs), and tissue revascularization, mapping these effects onto established models of fat graft take. The review aimed to identify potential interference points without conducting new experimental research.

The review identified several potential interference points where GLP-1 RAs could compromise fat graft survival. These include GLP-1-mediated adipocyte browning and thermogenic activation, characterized by the upregulation of UCP1 and mitochondrial uncoupling. Enhanced lipolysis was also noted through the upregulation of ATGL and HSL. Furthermore, GLP-1 RAs appear to suppress white adipogenic differentiation in ASCs, preferentially committing them toward thermogenic beige lineages. The drugs also modulate inflammatory and angiogenic signaling during the critical revascularization window, which is essential for graft integration. The growing off-label use of retatrutide introduces additional concerns due to its glucagon receptor-mediated lipolysis and thermogenesis. Despite these strong mechanistic rationales, the review highlighted a significant gap:

No clinical or preclinical studies have directly examined fat graft outcomes in patients receiving incretin-based therapies.